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An estimate of pocket closure and avoided needs
of surgery after scaling and root planing with
systemic antibiotics: a systematic review
Mirela Kolakovic1, Ulrike Held2, Patrick R Schmidlin1 and Philipp Sahrmann1*
Abstract
Background: Relevant benefits of adjunctive medication of antibiotica after conventional root surface debridement
in terms of enhanced pocket depth (PD) reduction have been shown. However, means and standard deviations of
enhanced reductions are difficult to translate into clinical relevant treatment outcomes such as pocket resolution or
avoidance of additional surgical interventions. Accordingly, the aim of this systematic review was to calculate odds
ratios for relevant cut-off values of PD after mechanical periodontal treatment with and without antibiotics, specifically
the combination of amoxicilline and metronidazol, from published studies. As clinical relevant cut-off values “pocket
closure” for PD ≤ 3mm and “avoidance of surgical intervention” for PD ≤ 5 mm were determined.
Methods: The databases PubMed, Embase and Central were searched for randomized clinical studies assessing the
beneficial effect of the combination of amoxicillin and metronidazole after non-surgical mechanical debridement.
Titles, abstracts and finally full texts were scrutinized for possible inclusion by two independent investigators. Quality
and heterogeneity of the studies were assessed and the study designs were examined. From published means and
standard deviations for PD after therapy, odds ratios for the clinically relevant cut-off values were calculated using a
specific statistical approach.
Results: Meta-analyses were performed for the time points 3 and 6 month after mechanical therapy. Generally, a
pronounced chance for pocket closure from 3 to 6 months of healing was shown. The administration of antibiotics
resulted in a 3.55 and 4.43 fold higher probability of pocket closure after 3 and 6 months as compared to mechanical
therapy alone. However, as the estimated risk for residual pockets > 5 mm was 0 for both groups, no odds ratio could
be calculated for persistent needs for surgery. Generally, studies showed a moderate to high quality and large
heterogeneity regarding treatment protocol, dose of antibiotic medication and maintenance.
Conclusion: With the performed statistical approach, a clear benefit in terms of an enhanced chance for pocket
closure by co-administration of the combination of amoxicillin and metronidazole as an adjunct to non-surgical
mechanical periodontal therapy has been shown. However, data calculation failed to show a benefit regarding
the possible avoidance of surgical interventions.
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Background
Periodontitis is a widespread inflammatory disease of
the tooth-supporting soft and hard tissues [1-3] with an
intermittent destruction process. It progresses either
chronically or aggressively [4], but in either case, bacter-
ial involvement in biofilms is regarded as the primary
etiologic factor for both disease initiation and progression
[5,6]. Accordingly, the pivotal aim of cause-related peri-
odontal therapy is based on the removal of the pathogenic
microbial challenge and the successful prevention of its
re-establishment in the ecological niches [7]. Clinically,
this is achieved by mechanical debridement using scalers,
curettes and/or ultrasonic instruments along with proper
oral hygiene instruction [8,9]. In this context, however, a
complete root surface cleaning has been shown to be an
unrealistic aim: Especially in pockets exceeding a depth of
6 mm, a perfect debridement is impossible - even when
performed by experienced operators [10,11]. Despite these
technical limitations, relevant outcome parameters like
depth and number of pockets can be significantly reduced
and maintained irrespective of the initial probing depth
[12,13]. However, in many situations periodontitis is not
completely resolved by non-surgical mechanical means
alone [14], especially in difficult to clean areas such as
multi-rooted teeth and complex bone defect configura-
tions [15].
Thus, the use of antimicrobials is a viable approach to
improve the clinical outcomes. The adjunctive adminis-
tration of systemic antibiotics for instance has been
shown to offer special healing benefits to improve the
mechanical debridement in critical sites [16]. In addition,
periopathogenic bacteria are known to colonize not only
subgingival tooth surfaces but also hide in oral niches like
deep plications of the tongue, crypts of the palatopharyn-
geal tonsils or the inner buccal mucosa and its recesses,
where they are mostly out of the reach of mechanical
treatment [17,18]. Noteworthy, some bacteria were even
shown to invade periodontal soft tissue cells [19-21],
where they remain inaccessible for conventional mechan-
ical debridement as well. Therefore, antibiotic therapy has
gained a long tradition in periodontitis therapy [22]. How-
ever, well-controlled studies are limited to specific agents
[23], among which, amoxicillin, metronidazole and their
combination being the most frequently investigated an-
tibiotics [24]. To date, a considerable number of studies
have consistently shown a superiority of the systemic
administration of these agents together with scaling and
root planning (SRP), mainly in terms of probing pocket
depths (PPD), clinical attachment levels (CAL) and
changes as compared to SRP alone [24]. However, the
problem of adverse side-effects and especially a seemingly
ever increasing risk of bacterial resistance [25] urge clini-
cians to balance risks and benefits well with each individ-
ual patient.
Among parameters for oral hygiene, marginal inflamma-
tion and gingival recession, periodontal pocket depth
(PPD) and clinical attachment loss (CAL) are still the
most important surrogate parameters for clinical changes.
Whereas CAL indicates the amount of periodontal de-
struction that will not necessarily be recovered in most
cases with successful periodontal treatments, PPD is the
parameter that should improve significantly during ther-
apy. As PPD values up to 3 mm are regarded as being
compatible with periodontal health, pockets exceeding
5 or 6 mm might not align with immediate treatment
success or long-term stability. As these pockets show a
significantly enhanced risk for further bacterial regrowth
and attachment loss [26], they constitute an indication for
additional – in most cases surgical - treatments. This fact
is well reflected in the cut-off values for pocket depths
of the Community Periodontal Treatment Index of
Treatment Needs (CPITN) and the Periodontal Screening
Record (PTR) [27,28]. hoo.de > ly dation section tge lan-
guage t in its te added. the phrase into. “ text as follows:
ults in enhanced heterogeneit.
Following the guidelines for the conduction of the
respective studies, systematic reviews with meta-analyses
present differences of various treatment modalities
expressed as means and standard deviations of the above-
mentioned outcome parameters (e.g. PPD and/or CAL) in
millimeters [29-31]. Despite being statistically flawless,
this mode of data presentation renders it difficult for clini-
cians and patients to estimate the clinical benefit in terms
of an adjunctive treatment [32], as direct information on
the degree of clinical success rate is not provided. Regard-
ing a clinically applicable success estimation after peri-
odontal treatment, the reduction of the periodontal
pocket depth on a physiologic level of up to 3 mm, i.e. the
clinical pocket closure, remains the most important end
parameter. Beyond that, a further distinction between sites
with moderately enhanced pocket depths that might re-
main stable over long time periods and those, which most
probably need further invasive therapy, seems reasonable
[26]. Thus, distinct cut-off values of ≤ 3 mm and ≤ 6 mm
PPD might constitute important landmarks to clinicians
and patients for every day decision-making.
Therefore, it was the aim of the present study to con-
duct a meta-analysis based on data of the existing litera-
ture on combined administration of amoxicillin and
metronidazole as an adjunct to SRP, calculating the prob-
ability of clinical success by using these relevant cut-off
values of 3 an 5 mm PPD to provide estimated for pocket
closure and avoidance of surgery after scaling and root
planing with systemic antibiotics.
Methods
This study was planned and conducted in accordance
to the PRISMA guidelines for systematic reviews [29].
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Modifications were made with regard to the study specific
presentation of the outcomes expressed as means and
standard deviations instead of estimated probability for
the cut-off values.
The focused question according to the PICO criteria
was:
“What is the outcome after non-surgical subgingival
debridement with or without systemic administration
using a combination of amoxicillin and metronidazole in
healthy humans with chronic or aggressive periodontitis in
terms of the estimated odds ratio for pocket closure (i.e.
PPD ≤ 3 mm) or avoidance of surgery (i.e. PPD ≤ 5 mm)?”
A meta-analysis was conducted for data at 3 and
6 month after intervention.
Search strategy
A literature search up to June 2013 was conducted in the
US National Library of Medicine (PubMed), the Exerpta
Medical Database (Embase) and the Cochrane Central
Register of Controlled trials (CENTRAL) using the search
terms and combinations presented in Figure 1. After title
and abstract screening, an additional hand search was per-
formed in the reference lists of all full texts of interest and
the index of contents of Journal of Clinical Periodontology,
Journal of Periodontal Research and Journal of Periodon-
tology. The search was conducted without language
restriction. The literature search was performed by two in-
dependent reviewers (Kolakovic and Sahrmann). In case
of discrepancies, study exclusion was determined after
discussion. The search strategy is depicted in Figure 2.
Eligibility criteria
In order to include data from studies of highest quality,
only randomized controlled clinical trials were considered.
Studies comparing the clinical outcomes of non-surgical
periodontal treatment with and without adjunctive sys-
temic antibiotic therapy focussing on the combination
of amoxicillin and metronidazole, in otherwise healthy
patients were included. Studies had to report data for
periodontal probing depths after a time interval of at
least 3 months after treatment, presented as means and
standard deviations, which displayed normal data distri-
bution. Studies on patients with known diseases or drug
intake that potentially affects progression and therapy
of periodontitis (diabetes, immunosuppressive medication
etc.) were excluded. In order not to exclude an entity that
is often specifically treated with a concomitant antibiotic
medication smokers were not excluded.
Assessment of heterogeneity
To assess the comparability of the selected studies, data
on diagnosis, patient populations, exclusion criteria,
treatment protocols including pre-treatment, interven-
tions and maintenance protocols of each study were
extracted.
Quality assessment
To estimate the potential bias of the different studies
included, the described method of randomization, the
concealment strategy of the allocation and the blinding
of the operator performing the clinical examination
were assessed.
Statistical analysis
From each study, we extracted the number of participants
and the mean pocket depth and standard deviation at the
follow-up examination(s). If not exactly described in the re-
spective statistical methodology section in the original
Figure 1 Search items for the electronic literature search. MeSH – Mdical Subject Headings, TIAB – Title and Abstract.
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paper, we assumed that the pocket depths were normally
distributed if they were presented as mean and standard de-
viation. Based on available data sets, the probability of clin-
ical success, expressed as the proportion of pockets < 3 mm,
and the proportion of persisting pockets > 3 mm and >
5 mm, respectively, using the method proposed by Hauri
and co-workers [32] was determined. For this purpose,
the odds ratios (OR) and their 95% confidence intervals
from the derived event rates in experimental and control
group for each of the studies were calculated. For pooling
of these ORs a fixed effects meta-analysis model was used.
All analyses were performed with R, a free software envir-
onment for statistical computing and graphics [33].
Results
Study selection
The electronic literature search provided 1603 potentially
includable studies. Based on titles and abstracts, 1537 of
these were excluded (93% agreement between reviewers
prior to discussion). Based on the full text assessment
further 40 studies were excluded due to administration
of antibiotics other than the combination of interest,
data presentation without means and standard devia-
tions or inadequate intervention in either test or control
group (see Figure 2 and Table 1 [34-58]). In case of
missing clinical data or unsuitable data presentation the
corresponding authors were contacted via electronic
mail requesting further information, [59,60]. If no reply
was received within 12 weeks, the respective study had
to be excluded. The remaining studies could not be in-
cluded into the meta-analysis due to their individual
time points of data evaluation.
Study heterogeneity and study characteristics
In some studies smokers were excluded [61-64], one study
included only smokers [65] while others [66-75]
Figure 2 Screening strategy performed by two independent reviewers. vWC – vanWinkelhoff Cocktail.
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Table 1 Excluded studies
Excluded studies Reason for exclusion Reason group
Akincibay 2008 [34] Doxicyclin in the control group 2
Carvalho 2005 [35] No PPD data presentation as means ± standard deviation 1
Cionca 2010 [36] No PPD data presentation as means ± standard deviation 1
Ehmke 2003 [37] No PPD values given before and after treatment 1
Ehmke 2005 [38] No PPD data presentation as means ± standard deviation 1
Eickholz 2013 [39] no adequate control group 2
Eisenberg 1991 [40] short term evaluation (after 3 weeks) 5
Flemmig 1998 [42] No PPD data presentation as means ± standard deviation 1
Griffiths [55] no adequate control group 2
Guerrero [34] No PPD data presentation as means ± standard deviation 1
Haffajee [44] Administration of metronidazole only 3
Haffajee 2008 [43] Administration of metronidazole only 3
Hartmann 1986 [44] Administration of metronidazole only 3
Hernandez 1987 [45] No PPD data presentation as means ± standard deviation 1
Jenkins 1989 [46] no adequate control group 2
Joyston 1984 [47] Administration of metronidazole only 3
Joyston 1986 [48] Administration of metronidazole only 3
Lindhe 1982 [49] no adequate control group 2
Loesche 1987 [50] Administration of metronidazole only 3
Loesche [35] Administration of metronidazole only 3, 4
Surgical intervention
Loesche 1992 [51] Administration of metronidazole only 1, 3
No PPD data presentation as means ± standard deviation
Loesche 1993 [52] Administration of metronidazole only 1, 3
No PPD data presentation as means ± standard deviation
Lu 2012 [53] No PPD data presentation as means ± standard deviation 1
Lundstrom 1984 [54] no adequate control group 2
Magnusson 1984 [8] No administration of metronidazole 3
Mombelli 2005 [55], Giannopoulou 2006 [84] Administration of retraction chord, PrefGel® and PGA 1
Moreira 2007 [85] No group without antibiotics 2
Müller 1986 [86] Administration of metronidazole only 3
Noyan 1997 [87] no adequate control group 2
Palmer 1998 [88] Administration of metronidazole only 3
Palmer 1999 [89] Administration of metronidazole only 3
Re 1988 [90] No administration of metronidazole 3
Sigusch 2000 [56] no adequate control group 2
Sigusch 2001 [57] no adequate control group 2
Soder 1990 [91] Administration of metronidazole only 3
Soder 1999 [61] Surgical intervention 4
Sterry 1985 [92] Surgical intervention 4
Tinoco 1998 [93] Surgical intervention 4
Varela 2011 [94] Same data as Heller [45] -
Vergani 2004 [95] no adequate control group 2
Winkel [48] Administration of metronidazole only 3
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included both or even did not report on the smoking
status of their study population.
Generally, periodontitis cases were classified as general-
ized chronic or aggressive periodontitis or were not fur-
ther classified. Not every study reported explicitly to what
extent oral hygiene instructions were given before treat-
ment. Frequency and method of supragingival cleaning re-
mains unclear in some studies [67,69,70,73-75]. Test- and
control interventions were performed either as full
mouth or quadrant-wise treatments with either hand
instruments, ultrasonic devices or both. All studies used
local anesthesia during subgingival cleaning. Prescribed
antibiotics varied in concentration (375–500 mg for
amoxicillin and 250/400/500 mg for metronidazole,
three times a day each) and the period of intake (7, 10
or 14 days). Different modes of controlling the drug
adherence were described. The post-interventional care
varied in terms of the use of antiseptic solutions like
chlorhexidine of different concentrations and pharmaco-
logical forms (gel, mouth washes) and concentrations
(0.1/0.12/0.2/1.0%). The periods of investigation varied
from 3 to 24 months (Table 2).
Quality assessment
The quality assessment is presented in Table 3. If the
method of randomization, concealment or the blinding
of the examiner was clearly described, the quality was
rated as “+” if it was claimed that randomization, con-
cealment or the blinding was performed but no informa-
tion about the mode of performance was provided the
rating was “(+)” and if no concealment or blinding was
stated, the rating was “–”. Based on this rating, study
quality was assessed as moderate to high.
Study outcomes
For the re-evaluation time points we performed two
meta-analyses, one at 3 months after treatment and one
after 6 month, which included 10 and 7 studies with a
total of 521 and 448 patients, respectively.
The meta-analyses revealed that the use of the com-
bination of amoxicillin and metronidazole together with
SRP increased the chance of pocket closure by a factor
of 3.55 three month after the therapy (Figure 3) and a
pronounced 4.43 fold chance six month after the treat-
ment (Figure 4).
We found that it was not possible to calculate the risk
estimation for residual pockets exceeding 5 mm, as there
was an estimated risk for residual pockets over 5 mm of
0 for both treatment types, which rendered the com-
parative calculation impossible.
The estimated percentage for pertinent pockets exceed-
ing 3 and 5 mm for the additional use of antibiotics and
for SRP alone is presented in Table 4a (at time point
3 months) and b (at time point 6 months).
For two additional studies [62,71] with data given for
both the means and standard deviations and the exact
proportion of residual pockets, we performed the same
estimation like for the included studies in order to re-
validate the statistical model (Table 5). The comparison of
published and calculated ratios show a qualitative accord-
ance. However, some subgroups showed considerable dif-
ferences in size.
Discussion
This study aimed to estimate the chance of pocket clos-
ure or avoidance of surgical therapy after non-surgical
periodontal treatment comparing the treatment with
and without the additional use of the combination of the
amoxicillin and metronidazole. Other than in conven-
tional systematic reviews and different to the data pres-
entation recommended by the PRISMA statement [76],
this review did not present the differences by means and
standard deviations, but estimated the likelihood for the
attainment of clinical relevant surrogate parameters. We
Table 1 Excluded studies (Continued)
Studies not appliable to the meta-analysis
Berglundh 1998 [62] 5
Carvalho 2004 [63] 1
Casarin 2012 [96] 1
Goodson/Mdala 2012 [97] 1
Haffajee [44] 1
Moeintaghavi [38] 5
Ribeiro [39] 1
Rooney [46] 1
1 – missing PPD values as means ± std.
2 – no adequate control group.
3 – no combined administration of amoxicillin and metronidazole.
4 – surgical intervention.
5 – time point of re-examination.
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Table 2 Study description
Autor, year
of publication
Population Diagnosis Treatment
prior to
intervention
Intervention
test/control
Intervention Control Parameter
assessment
Invest.
period
Maintenance Exclusion Smokers Mean age,
gender
Aimetti [36] n = 39 systemically
healthy; ≥20 teeth
excluding teeth
indicated for
extraction and ≥2
sites around at least
12 teeth with CAL
and PD ≥6 mm
gen. aggr.
periodontitis
Supragingival
Sc and polishing,
ohi including
Bass technique
and id cleaning,
tongue 1x/d
1w after
screening:
OSFMD, SRP
in 2 sessions
within 24 h
(Us), no time
limit, dorsum
brushing with
1% CHX gel,
mouth rinse
2x/d 0.2% CHX,
pharynx sprayed
(4x tonsil) with
0.2% CHX spray,
all pockets
irrigated 3x
within 10 min
with 1% CHX
Gel, repeated
8d later; for 2
m: 0.2% CHX
2x/d, tonsil
spray 2x
n = 19 OSFMD+
A 500 mg+M
500 mg 3x/d
for 7d
n = 20
OSFMD +
Placebo
Presesence of
plaque BOP PD
Rec CAL (PD +
Rec) at 6 sites
around all
present teeth
BL, 3 m, 6 m
6 m Every 2d to
reminder to take
medication; no
control of empty
bottles; check CHX
staining, ohi
reinforced,
full-mouth
supraging
debridement and
professional cleaning
on a 2w intervall in
first 6w and every
2 m up to 6 m
evaluation
Medical disorders
or consumption
of drugs affecting
periodontal status,
AB therapy within
last 6 m, long-term
administration of
antiinflammatory
drugs, periodontal
treatment in
previous 6 m, preg
nancy, lactation
Excluded Age T: 36.3 ± 3.2
C: 35.7 ± 2.8
Gender T: 58% f
C: 50% f
Cionca [29] n = 47 (4 drop-outs)
systemically healthy,
≥12 teeth, no
orthodontic
appliances, no fixed
prostetics, no implants,
≥4 teeth with PD
>4 mm, CAL ≥2
mm+ rx bone loss.
adult chronic
periodontitis
supraging Sc,
ohi after 10d:
check oral
hyg and
re-instruction
FM debridement
in 2 visits within
48 h: subgingival
ScRp: Us, then
Gracey, 0.1%
CHX, at home
0.2% CHX for
10d 2x/d at the
end of final
treatment:
medication
Parallel design
n = 23M
500 mg + A
375 mg 3x/d
7d
n = 24
Placebo
GI, PD, BOP,
REC (on 6 sites
of teeth with
PD >4 mm at
BL); Plaque (6
sites, all teeth);
microbiological
sample at BL,
3 m, 6 m
6 m 10d post-treatment:
compliance control,
bring back the
medication remained;
recall 1w, 3 m, 6 m
after medication:
ohi reinforced,
supragingival
calculus removed
Systemic diseases,
pregnancy, lactation,
systemic AB within
last 2mt, use of
NSAID, periodontal
treatment within
last year
Recorded 25-70y
Feres
2012 [41]
n = 118 (at 6 m 5
drop-outs, at 12 m
17 drop-outs); good
gen health; ≥30y;
≥6 teeth with at
least 1 site each
with PD and CAL
≥5 mm, at least
30% of sites with
PD and CAL
≥4 mmm and BOP
gen chronic
periodontitis
ohi, same
dentifrice
(Colgate total)
SRP in 4–6
session for 1 h
each, manual
instruments;
entire oral
cavity within
14d
Immediately
after first
session of SRP
n = 39M
400 mg 3x/d
14d CHX +/-
n = 39 SRP +M
400 mg + A
500 mg 3x/d
14d CHX +/-
CHX: rinse
15 ml 0.12%
CHX or placebo
for 1 min 2x/d
2 min
n = 40
SRP +
Placebo
CHX +/-
visible plaque
gingival bleeding
BOP Suppuration
PD (at 6 sites)
CAL (at 6 sites)
Hu-Friedy BL,
3 m, 6 m, 12
12 m At 3 m, 6 m, 12 m;
at the end of each
week of medications
asked to return
bottles/flasks;
questionnaire about
self-perceived side
effects; calling
subjects every 2d
to monitor
AB-compliance
Previous subgingival
periodontal therapy,
pregnancy, nursing,
systemic diseases
affecting periodontal
status, long-term ad
ministration of anti-
inflammatory drugs,
need for
AB-premedication
for routine dental
therapy, AB therapy
within last 6 m,
allergy to M, A or
CHX
Excluded C: 45.8 ± 8.54y
12 m/28f M:
43.4 ± 8.26y
15 m/24f MA:
46.3 ± 8.59y
17 m/22f
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Table 2 Study description (Continued)
Heller [45] n = 31 (4 drop-outs)
≥16 teeth; ≥4 sites
on different teeth
with PD ≥6 mm,
CAL ≥5 mm,
moderate to
severe bone
loss and BOP
gen aggr
periodontitis
ohi in 2 weekly
sessions, aim
<20% PlI
Phase I: FM
debridment
with Us 2x1h,
irrigation of all
pockets with a
gel 0.2% CHX
within 24 h,
rinse and
gargle 2x/d
with 0.12%
CHX, brush
tongue 2x/d
with gel for
45d. After
last session
assigned to
group test
or control.
Phase II:
quadrant
scaling
manual 1 h
within 4-6w;
irrigation of
pockets: 0.2%
CHX Parallel
design
n = 18 A
500 mg +M
250 mg 3x/d
10d
n = 17
Placebo
Clin exams at
BL, 3 m, 6 m 6
sites per tooth
PD and CAL
BOP + or –
Plaque GI
Suppuration
BL, 3 m, 6 m
6 m 3 m follow up visit:
ohi reinforcement,
FM supragingival
cleaning; sites with
PD > 4 mm and
BOP were
reinstrumented
unter LA
Allergy to penicillin,
M or CHX, systemic
diseases affecting
periodontal status,
longterm-used
antiinflammatory
medication,
periodontal
treatment or AB
in last 6 m,
pregnancy, lactation
No data 18-39y
Matarazzo
[40]
n = 43 (2 drop-outs)
≥15 teeth, ≥6 sites
with PD 5-7 mm
and CAL 5-10 mm
chronic
periodontitis
Clinical and
mikrobiological
monitoring, FM
supragingival
scaling, ohi,
same
toothpaste
(Colgate total)
SRP in 4-6x ap
pointments 1 h
each within max
of 21d, AB
therapy
initiated at first
SRP visit
n = 14 SRP A
400 mg M
400 mg 3x/d
14d n = 14
SRP +M
400 mg + A
500 mg 3x/d
14d
n = 15
SRP +
Placebos
Visible plaque
gingival
bleeding BOP
Suppuration PD
CAL at 6 sites,
Hu-Friedy BL,
3 m
3 m Had to bring tubes
containing medication
at every SRP visit (pills
were counted); calling
every 4d to monitor
compliance
Aggr periodontitis,
pregnancy, lactation,
periodontal or AB
therapy in previous
6 m, systemic
conditions affecting
progression of
periodontal disease,
longterm
administration of
antiinflammatory
drugs, need for AB
coverage for routine
dental therapy,
allergy to M and/or
penicillin
Only
smokers
at least
10 cig/d
for last 5y
All >30y age
SRP: 40.5 ± 8.2 y
SRP +M: 40.8 ±
5.1 y SRP +M+
A: 42.8 ± 7.1 y
gender SRP:
7/8 m/f SRP +M:
7/8 (6/8) m/f
SRP +M+A: 7/8
(6/8) m/f
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Table 2 Study description (Continued)
Mestnik [37] n = 30 systemically
healthy, ≥ 20 teeth,
≥6 permanent teeth
including incisiors
and/or first molars
with PD and CAL
≥5 mm and ≥6
teeth other that first
molar and incisors
with at least one site
each with PD and
CAL ≥5 mm, familiar
aggregation
gen aggr
periodontitis
FM supraging
Sc and ohi,
same Dentrifice
(Colgate total)
FM SRP in
max 6 sessions
1 h within 14d,
manual
instruments;
rinsing with
15 ml 0.12%
CHX 1 min
2x/d 60d. AB
and CHX rinses
starts immediately
after 1. session of
mechanical
instrumentation.
n = 15 SRP M
400 mg + A
500 mg 3x/d
for 14d
n = 15
SRP und
Placebo
Visible plaque
Gingival
bleeding BOP
Suppuration
PD CAL at 6
sites BL, 3 m
3 m 1x/w bring packs
back, check
compliance; calling
every 2d to monitor
compliance
Previous subgingival
periodontal therapy,
smoking, pregnancy,
systemic desease
affecting
progression of
periodontal disease,
long-term
administration of
anti-inflammatory
medication, need
for AB coverage
for routine dental
therapy, AB therapy
in previous 6 m,
allergy to CHX, A, M
Excluded ≤30y Age T:
26.8 ± 3.9 y C:
27.6 ± 3.5 y
Gender T: 6/9
m/f C: 4/11 m/f
Mombelli
[24]
n = 82 systemically
healthy, ≥12
scorable teeth (no
3th molars, no teeth
with orthodontic
appliances, bridges,
crowns or impl),
diagnosif of
periodontitis with
≥4teeth with PD
>4 mm, CAL ≥2 mm
+ rx evidence of
bone loss
chronic
periodontitis
(untreated
moderate to
advanced)
supragingival
cleaning, ohi,
recalled to
assure good
oral hygiene
SRP within 48 h
usually in 2
sessions with Us,
Gracey curettes,
then irrigated
the pockets
with 0.1% CHX;
at home rinse
2x/d for 10d
with 0.2% CHX
n = 22 Aac - n =
22 Aac + SRP+
500 mg M+
375 A 3x/d
for 7d
n = 19
Aac -
n = 19
Aac +
SRP +
Placebo
GI PD REC BOP
Suppuration PS
(6sites of all
teeth) on 6 sites
of each tooth
with PD >4 mm
at BL BL, 3 m
3 m 1w after treatment:
return any
medication left
systemic illnesses,
pregnancy,
lactation, AB taken
within previous
2 m, use of
NSAIDs, confirmed
or suspected
intolerance to
5-nitroimidazole-
derivates or A,
subgingival SRP or
surgical periodontal
therapy in the last
year
Recorded 25-70y T: 21
females 17
smokers C: 20
females 12
smokers
Preus [99] n = 180 (4 drop-outs)
no prior systematic
periodontal
treatment, after
pre-study hygiene
phase ≥5sites with
PD ≥5 mm
remained,
moderate
to severe
oeridontitis
3 m hygiene
phase: ohi,
supraging. Sc,
necessary
extraction,
endodontic
treatment,
filling and
temporary
prosthetics
done by
general dentist
Gr 1 + 2: FM SRP
(FMD) completed
within a single
workday in 2x
65 min, 2 h apart,
SRP completed
in 2x 65 min
each, 21d apart
All: rinsed for 1
min with 10 ml
0.2% CHX; Us,
hand and rotating
instruments, first
1. + 4.Q, second
2. + 3 Q; air-flow
or pumice paste;
contact points
flossed, sulci +
n = 44 FMD +M
400 mg 3x/d
10d n = 45
SRP+M 400 mg
3x/d 10d
n = 45
FMD +
Placebo
n = 46
SRP +
Placebo
PD CAL Plaque
yes no BOP 4
sites of all teeth
BL, 3 m, 12 m
12 m After 7d a quality
control of the
scaling and 7w later
(8w posttreatment)
reinforcement of
ohi Supportive
treatment sessions
at 3, 6, 12 m after
active therapy
Syst diseases known
to be associated
with perio,
contunuous
medication known
to affect perio,
allergy to M
Recorded 35-75y Gr1:
53.7 ± 7.6y 43.5%
women 47.8%
current smokers
93.5% current/
former smokers
Gr2: 55.1 ± 7.9y
62.2% women
53.3% current
smokers 75.6%
current/former
smokers Gr3:
56.8 ± 8.3y
43.5% women
63.0% current
smokers 84.8%
current/former
smokers Gr4:
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Table 2 Study description (Continued)
pockets filled
with a 1% CHX
gel Home care in
structions in brush
ing teeth and
tongue and rinse
with 0.2% CHX:
every morning
for 9d parallel
design
54.9 ± 8.5y 51.1%
women 57.5%
current smokers
95.7% current/
former smokers
Sigusch
2001 [57]
n = 25 (M) systemically
healthy, average of 16
sites with PD >8 mm
and intrabony lesion
at≥ 1–5 teeth over
two-thirds of the
root length
gen rapidly
progressive
periodontitis
1.step: SRP in
4–5 sessions
including ohi 2.
step: 3w later
FM Rp in 1 or 2
2 h -sessions
with no more
than 2d between
sessions, wound
dressing
First dose
immediately
after the 2.step
n = 12 Doxy
n = 15M
2x500mg,
8 days n = 11
Clindamycin
n = 10 BL, 3w after SRP
(first step), 6 m,
24 m after
enhanced Rp
(second step) PI
Sulcus BI PD CAL
Suppuration at
six sites per
tooth
6 m,
24 m
Recall sessions every
4-6w for 6 m and
every 12w thereafter
AB therapy within
last 6 m, history of
recurrent disease
other than
periodontitis; flap
surgery in the past
6y
Excluded,
unless
they had
stopped
smoking
2 m prior
to therapy
Mean age:
32.4y Gender
m/f 20/28
Winkel [48] n = 21 > 25y, ≥3
natural teeth in each
quadrant; ≥1 site with
PPD >5 mm with BOP
and rx evidence of
bone loss in each
quadrant
gen adult
periodontitis
FM initial perio
dontal treatment:
SRP and ohi, 3–6
sessions of 1 h,
at each session
ohi reinforced.
6w after last
SRP session:
FM check up
and SRP if PD
> 3 mm and
BOP. Ohi and
reinforcment
n = 10 A
500 mg +
Clavulanic
acid 125 mg
3x/d for 10d
n = 11
SRP
PPD CAL
constant force
probe, Brodontic
PI GI BOP
BL,
3 m,
6 m,
9 m,
12 m
Recording time of
intake medication
on a diary; returned
the unused pills, call
2w after the end of
the medication
hypersensitivity
toward ß-lactam
agents, professional
SRP or surgical
periodontal therapy
in the past and AB
therapy 6 m prior
to treatment,
pregnancy, lactation,
planing pregnancy,
systemic disease,
acute necrotising
periodontitis; use of
non-steroidal
anti-inflammatory
drugs
Smoker: T:
5 C: 5
Gender m/f T:
2/8 C: 4/7 age
T: 49y (36–66)
C: 39y (28–47)
Winkel [49] n = 49 ≥ 3 natural
teeth in each
quadrant; ≥1 site
in at least 3 of the 4
quadrants with PPD
>6 mm and CAL
≥3 mm, BoP and
radiographic
evidence of
alveolar bone loss
no data FM SRP in 3–6
sessions of 1 h,
at each session
ohi reinforced
6w after 1st
session: recall
for FM check-up
and SRP at sites
with PD >3 mm
and BOP, including
ohi reinforcement.
on this day:
medication
n = 23 A
375 mg +M
250 mg 3x/d,
7d
n = 26 PI PPD BI
(bleeding index)
CAL
BL,
6 m
Ohi reinforcement
at every SRP session
and after 6w return
med after 7d
SRP or surgical
periodontal
therapy; periodontal
AB therapy 6 m
prior to the initiation
of the study;
pregnancy, lactating
or planing
pregnancy; systemic ;
acute necrotising
periodontitis; use
of NSAIDs, use of
mouthrinses
Recorded.
smoker =
also if had
stopped
within the
last year T:
14/23 C:
18/26
mean age 42y
(28–63) mean
age T: 45y
(32–63) mean
age P: 40y
(28–55) gender
m/f T: 11/12 C:
10/16
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Table 2 Study description (Continued)
Xajigeorgiou
[50]
n = 43 (4 drop-outs)
n = 33 (A + M) ≥20
teeth,
gen aggr
periodontitis
(with amiliar
aggregation)
BL sampling of
subging plaque
and FM clinical
recordings
Ohi and FM SRP,
4 visits; f PI ≤20
continued after
the 6w;
debridement
n = 10 SRP M
500 mg + A
500 mg 3x/d,
7d n = 12 SRP+
M 500 mg
3x/d, 7d
n = 11
SRP
BL 6w after
SRP 6 m PD
(Hu-Friedy) AL
BOP at six sites
6 m reinforcement of
ohi biweekly from
BL to 6w
AB intake in the
last 3 m, AB
allergies,
periodontal
treatment during
previous 12 m,
pregnancy, lactation
Recorded
MA 3/10 M
5/12 C
4/11
Age 22-49y
M + A 38.9 ±
8.7 M 40.9 ±
4.6 C 37 ± 5.6
Gender m/f
M + A 5/5 M
4/6 C 6/5
A→ Amoxicillin.
AB→ antibiotics.
aggr→ aggressive.
AL→ Attachment level.
BOP→ Bleeding on probing.
CAL→ clinical attachment level.
CHX→ chlorhexidine.
d→ day/days.
FM→ full mouth.
FMPS→ Full Mouth Plaque Score.
FMBS→ Full Mouth Bleeding Score.
GBI→ gingival bleeding index.
gen→ generalized.
GI→ Gingival index.
id→ interdental.
io→ intraoral.
loc→ localized.
m→month(s).
M→Metronidazole.
m/f→ ratio males/females.
NSAID→ non steroid anti-inflammatory drugs.
ohi→ oral hygiene instruction.
OSFMD→One Stage Full Mouth Disinfection.
PD→ probing depth.
PI→ plaque index.
pol→ polishing.
PS→ Plaque score.
REC→ Recession of the gingival margin.
rx→ radiographic.
Sc→ scaling.
SRP→ Scaling and Root planing.
Us→ Ultrasonic device.
VPI→ visible plaque index.
w→week(s).
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believe that this kind of data presentation provides easier
and clinically more relevant interpretations of the clin-
ical effectiveness, as in periodontal treatment the main
target is the reduction of pockets below a cut-off pocket
depth of less than 3 mm or not exceeding 5 mm [26]: The
first benchmark indicates that the pockets are “closed”
with no further treatment needs, whereas the second
benchmark indicates the avoidance of specific needs for a
surgical intervention, which is classically still indicated if
pockets of 6 mm depth and deeper persist after treatment
Table 3 Quality assessment
Author, year of publication Method of randomisation [+/(+)/-] Concealment [+/(+)/-] Blinding of the examiner [+/(+)/-]
Aimetti [36] + + +
Computer generated list
Cionca [43] + + +
Computer generated list
Ferres 2012 [41] + + +
Computer generated list
Heller [45] + + +
Computer generated list
Matarazzo [40] + + +
Computer generated list
Mestnik [37] + + +
Computer generated table
Mombelli [24] + + +
Computer generated list
Preus [99] + + +
Computer generated table
Sigusch 2001 [57] (+) - (+)
Winkel [48] (+) - +
Winkel [49] (+) - +
Xajigeorgiou [50] + - +
Randomization table
+ modality explained.
(+) claimed without further explanation.
- not reported.
Figure 3 Meta-analysis of the chance for pocket closure after 3 months. OR – odds ratio, 95-CI – 95% confidence intervall, w – weight,
p – level of significance.
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due to their significantly enhanced risk for disease recur-
rence [26].
This study clearly elucidated an enhanced chance for
pocket closure when antibiotics were used in combin-
ation with mechanical root surface debridement. On the
other hand, the calculations could not be performed for
the case of a cut-off value > 5 mm. This implied that
the statistical model indicated a 100% elimination of
pockets > 5 mm for both the treatment with and without
the use of antibiotics. This fact depicts a shortcoming of
the performed statistical estimation, as the single studies
in fact reported isolated residual pockets.
In all the included studies, we assumed a normal dis-
tribution of the data [77]. With relatively small case
Figure 4 Meta-analysis of the chance for pocket closure after 6 months. OR – odds ratio, 95-CI – 95% confidence intervall, w – weight,
p – level of significance.
Table 4 Percent of persisting pockets deeper than 3 mm and 5 mm
Paper PPD > 3 mm PPD > 5 mm
Test (AB type = 1) Control (AB type = 0) Test (AB type = 1) Control (AB type = 0)
a) At 3 months follow up
Aimetti [36] 37 70 0 0
Cionca [29] 52 75 0 0
Feres 2012 [41] 26 55 0 0
Heller [45] 83 100 0 0
Matarazzo [40] 50 73 0 0
Mestnik [37,53] 27 60 0 0
Mombelli [24] Aac+ 36 58 0 5
Mombelli [24] Aac- 54 63 0 5
Preus 2013 [99], FMDIS 0 0 0 0
Preus 2013 [99], SRP 0 26 0 0
b) At 6 months follow up
Aimetti [36] 32 65 0 0
Cionca [29] 42 63 0 0
Feres 2012 [41] 15 53 0 0
Heller [45] 17 100 0 0
Mestnik [37,50] 13 60 0 0
Winkel [49] 52 76 0 0
Xajigeorgiou [50] 60 72 0 0
AB type 1 – systemic antibiotic administration.
AB type 0 – no antibiotic administration.
Aac + − Regarding Evaluation from subgroup positiv for A. actinomycetemcomitans.
Aac- - Regarding Evaluation from subgroup negative for A. actinomycetemcomitans.
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numbers, this expectation might have distorted the cal-
culated results to some extent. However, the effect of
possible statistical misclassification was likely to be similar
in test and control group due to the randomization of the
treatment allocation of the studies, thus limiting the dis-
turbing bias again.
We tried to verify the adaptability of the statistical
model using the calculation in studies that provided
both, means and standard deviations and the exact dis-
tribution of residual pockets of either > 3 mm or > 5 mm
depth. In the data of one study group [62,78] we found a
good correlation of true and calculated results. However,
in another the true and estimated values varied to a
greater extent [71], despite the fact that important factors
such as sample size were comparable.
The calculation model has been previously published
and more studies using this analysis methodology have
been demanded [32]. With the present data, its applicabil-
ity can be better understood and its limitation to studies
with higher numbers of participants appears recommend-
able. In conclusion, the data presentation of the exact dis-
tribution of the pocket depths over 3 and 5 mm – as
already presented in the actual literature – should be pro-
vided in future studies as it was done in the classical stud-
ies as well. However, such a request needs time to push
through and as long as this claim is not generally imple-
mented, the proposed statistical model offers a useful al-
ternative method to combine and compare study results
in such a way.
The pronounced effect of the antibiotics during healing
after the first three months as compared to healing after
SRP alone is well reflected well in our analysis: For pocket
closure, there is an enhanced chance after 6 month if anti-
biotics had been used. This finding is in accordance with
the existing literature [30,79,80].
A large heterogeneity existed for the included data:
Smoking status, diagnosis of aggressive or chronic peri-
odontitis and the detailed treatment scheme used in the
studies showed substantial variations. With the cumula-
tive analysis there was a certain risk of comparing apples
with oranges. However, this approach offered the possi-
bility to generate a universal conclusion on the antibiotic
treatment of periodontitis, regardless of which patients
were treated with which protocol. Furthermore, and an-
other limitation of our approach, we could not include
important studies assessing the issue of interest because
of the way on which their data was presented: Several
authors presented their data well and even with the
similar aim to refer to distributions of specific bench-
mark values, but unfortunately other cut-off values
than ours were chosen, which rendered a comparison
impossible.
With 10 and 7 included studies for the time points 3
and 6 months after treatment, respectively, only a rela-
tively small number of studies dealing with the issue of
antibiotics in periodontitis treatment could be included.
Zandbergen et al. assessed a body of 24 studies in a
classic review [30]. However, aiming to perform a
meta-analysis they could only calculate the overall
change of PD and CAL for SRP in combination with
antibiotics. Neither a direct comparison to the treat-
ment without antibiotics, nor an estimate of the treat-
ment success in terms of pocket closure or avoidance
of surgical therapy was possible in their review. These
aspects, however, are important to both the practi-
tioner and the patient.
The benefits of antibiotic treatment always have always
to be balanced against their possible adverse reactions.
For amoxicillin allergic skin reactions, joint swelling
and – in few cases – anaphylactic reactions are well
documented [81]. Metronidazole has frequently been
reported to cause – among other discomforts and in-
dispositions - nausea, diarrhea and headache [82]. The
dimension of the potential risk of causing resistant
strains against these antibiotics must also be kept in
mind, even if the discussion about this issue is contro-
versial in the current literature [25,82,83]. For the clin-
ician a clear prediction of the benefits of adjunctive
antibiotic therapy in therms of residual treatment
needs after non-surgical treatment might be an easier
and better tool for the consideration of a possible anti-
biotic prescription than rather abstract means and
standard deviations as predominantly presented in con-
ventional reviews.
Conclusion
Using a distribution based statistical approach, it was
shown that there is a clear benefit in terms of an enhanced
chance for pocket closure by co-administration of the
combination of amoxicillin and metronidazole as adjunct
to non-surgical mechanical periodontal therapy. However,
based on the currently available data a potential benefit in
terms of the possible avoidance of surgical interventions
could not be delineated.
Table 5 Comparison of published and calculated OR for
the use of antibiotics for studies providing both means
and standard deviations and percentages of residual
pockets
Study Cut-off [mm] Data 3 m 6 m
Rooney [46] 3 published 2.8 2.6
3 calculated 7 7
Mestnik [37,50] 5 published 1.7 2.2
5 calculated 1 2.2
Rooney [46] 6 published 11.3 9.5
6 calculated 3.4 2.2
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Appendix
The following formula for the calculation of the probabilities
P(X”x) for clinical success, ie, for pockets >3 mm was used:
F(X)(x) describes the cumulative distribution function,
the mean, the standard deviation and x the cutoff
value, eg 3 mm or 5 mm.
For the expression:
One can determine the probabilities by consulting normal
distribution tables [58]. stands for the distribution function
of the standard normal distribution. The probability values
in the Tables p ublished by Stahel are only valid for s tandard
normal distribution. For example, for a group of nine
patients, the mean pocket depth at followup is 3.53 mm
with a standard deviation of 0.62. Therefore, for:
We get ((3.00 − 3.53)/0.62) = −0.85. The probability for
pockets ≤ 3 mm is 0.20, as derived from the Table in
Stahel [58]. Hence, the number of patients with pockets
″Accordingly, the number of patients with pockets ≤ 3 mm
is 9 × 0.20 and the number of patients with pockets >3 mm
is 0.80×9 [32].
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